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Impacted bone allograft is often used in revision joint replacement. Hydroxyapatite 
granules have been suggested as a substitute or to enhance morcellised bone allograft. We 
hypothesised that adding osteogenic protein-1 to a composite of bone allograft and non-
resorbable hydroxyapatite granules (ProOsteon) would improve the incorporation of bone 
and implant fixation. We also compared the response to using ProOsteon alone against 
bone allograft used in isolation. We implanted two non-weight-bearing hydroxyapatite-
coated implants into each proximal humerus of six dogs, with each implant surrounded by 
a concentric 3 mm gap. These gaps were randomly allocated to four different procedures in 
each dog: 1) bone allograft used on its own; 2) ProOsteon used on its own; 3) allograft and 
ProOsteon used together; or 4) allograft and ProOsteon with the addition of osteogenic 
protein-1. 
After three weeks osteogenic protein-1 increased bone formation and the energy 
absorption of implants grafted with allograft and ProOsteon. A composite of allograft, 
ProOsteon and osteogenic protein-1 was comparable, but not superior to, allograft used on 
its own.
ProOsteon alone cannot be recommended as a substitute for allograft around non-
cemented implants, but should be used to extend the volume of the graft, preferably with 
the addition of a growth factor.
Restoration of bone stock is often a major
challenge in the revision of a loose total hip
replacement (THR). Morcellised fresh-frozen
femoral head allograft has given good results
when impacted to restore bone in femoral and
acetabular bone defects.1,2 Because of the risk
of disease transmission and the limited avail-
ability of bone allograft, alternatives are being
investigated. Calcium phosphate-based bone
substitutes such as hydroxyapatite (HA) have
been used to restore bone defects in the acetab-
ulum and the proximal femur.3 Mechanically, a
composite of calcium phosphate granules and
morcellised allograft might provide adequate
initial stability to be used to graft the femur.4
However, little is known about the biological
consequences of adding such bone substitute to
bone allograft. One problem associated with
the use of ceramics in this setting is the lack of
osteoinduction. Adding bone growth factors
such as osteogenic protein-1 (OP-1) (bone
morphogenic protein-7) to a composite of
morcellised bone allograft and HA granules
might increase the biological activity and
accelerate bone repair and fixation of the
implant.
The aim of this study was to investigate
whether HA granules could be used as a substi-
tute for bone allograft or be added to it to
expand the available volume. We also investi-
gated the effect of OP-1 on a composite of
bone allograft/HA granules. Evaluation was
based on mechanical testing of fixation of the
implant and studying bone histomorphometry
in a canine model.
Materials and Methods
The study was conducted using eight skele-
tally-mature Labrador dogs. One additional
dog served as the source of the allograft. The
dogs were bred for research and had a mean
age of 14 months (12 to 14) and a mean weight
of 29.3 kg (27.5 to 30.3). The protocol was
accepted by the Danish Animal Research Com-
mittee and the experiment was conducted in
accordance with Danish law.
The proximal humeri of each dog were used
for the implantation of two small metal
implants, leaving a 3 mm gap between the
implant and the host bone (Fig. 1).
The four gaps in each dog were randomised
to be grafted in group 1 with bone allograft; in
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group 2 with ProOsteon; in group 3 with allograft mixed with
ProOsteon and in group 4 with allograft mixed with ProOst-
eon to which OP-1 had been added. Allograft and ProOsteon
were mixed in equal volumes in groups 3 and 4. All pro-
cedures were carried out by the same operator (TBJ). The
intention was to blind all evaluations but as the grafting
materials were easily distinguishable, the operation and
histomorphometry could not be performed blinded. The
grafting materials were weighted pre-operatively and
packed into containers. The weight necessary to fill the gaps
was determined in pilot studies, and the materials were
mixed to be as homogenous as possible.
Grafting materials. Bone allograft. The proximal humerus
and the proximal and distal femur were harvested from a
dog not included in the study. The bone was frozen at -
80˚C for two weeks, then thawed and the soft tissue and
cartilage removed prior to milling  to produce chips that
ranged between less than 1 mm and 7 mm. The graft was
weighed into portions, packed into sterile containers and
re-frozen at -80˚C. All bone preparation was undertaken
under strict aseptic conditions in an operating theatre,
and bacterial cultures were taken to exclude any contam-
ination of the allograft.
ProOsteon 200 (Interpore, Irvine, California) is a cor-
alline porous HA bone substitute approved by the Food
and Drug Administration (FDA). It was provided as
granules with a diameter of 425 µm to 1000 µm and a
mean porous diameter of 200 µm.5 Before the operation,
it was weighed, placed in containers and autoclaved
according to the manufacturer’s instructions.
OP-1 was delivered as a preparation consisting of 2.5 mg
recombinant human OP-1 mixed with 1 g of bovine type I
collagen (Stryker Biotech, West Lebanon, New Hamp-
shire). A dose of 300 µg OP-1 with 120 mg of collagen car-
rier was mixed with ProOsteon/bone allograft prior to
grafting, reducing the volume of ProOsteon/allograft by
10% to accommodate the volume of OP-1.
Implants. Cylindrical titanium alloy (Ti-6A1-4V) implants
with a plasma-sprayed titanium porous coating were
manufactured by Biomet (Warsaw, Indiana). A 50 µm thick
HA coating with a calcium to phosphate ratio of 1.67 was
plasma-sprayed on the porous titanium alloy coating by
BioInterfaces Inc (San Diego, California). The final size of
the implants was 10 mm long and 5 mm in diameter. The
measured surface roughness (Ra) of the HA-coated
implants was 41 µm using a previously described method.6
The implants were sterilised by gamma irradiation. A
standardised 3 mm gap was maintained around the implant
on insertion into the prepared bed by a footplate and a
washer (Fig. 2).
Surgery. Under general anaesthesia and observing aseptic
precautions the proximal humeri of each dog were exposed
by a lateral extra-articular approach. A 1.8 mm guide wire
was inserted into the bone and two 11 mm diameter holes
were hand-drilled using a cannulated drill. The most prox-
imal implant was inserted immediately distal to the greater
tuberosity and the additional implant was placed 9 mm
more distally (Fig. 1). Before and after each operation, 1 g
ampicillin (Anhypen, Gist-Brocades, Delft, The Nether-
lands) was administered intravenously. In order to harvest
the experimental material the dogs were sedated with
Fig. 1a Fig. 1b
a) Radiograph and b) diagram of the proximal humerus showing the placement of the implants. Each implant was inserted into the proximal humerus.
After three weeks, the implants were divided into two; one half was used for histomorphometry, the other half was used for mechanical testing.
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methohexital (Brietal, Lilly, Denmark) and killed with an
overdose of potassium chloride three weeks after the
implantation.
Preparation of tissue samples. The retained proximal parts
of the humeri were stored at -20˚C. Sections perpendicular
to the long axis of the implant were made using a water-
cooled diamond bandsaw (Exact Apparatbau, Norderstedt,
Germany) as previously described.7 As a first step, the most
superficial 1 mm of the specimen was removed and dis-
carded. The following section, with a thickness of 5 mm,
was divided in half along the axis of the implant. One half
was randomly selected for histomorphometry. The other
was stored for an experiment on immunohistology which is
not included in the current report. The remainder of the
specimen, closest to the footplate, was stored at -20˚C and
used for mechanical testing.
Histomorphometry. The specimens were dehydrated in
70% to 100% ethanol containing 0.4% basic fuchsin and
subsequently embedded in methylmethacrylate (Techovit
7200 VLC; Exact Apparatbau). Four horizontal sections
50 µm in thickness were cut with a microtome (MePro-
Tech, Heerhugowaard, The Netherlands) and surface coun-
terstained with 2% light green for two minutes,8 to colour
all mineralised tissue green. Bone allograft was distin-
guished from newly-formed bone by the lamellar light-
green structure with empty lacunae, compared to the
darker woven structure of newly-formed bone. ProOsteon
stained brown and the collagen carrier from the OP-1
device had a reddish colour with this technique (Fig. 3).
The field of view obtained with the microscope was
transmitted to a computer screen. Histomorphometry was
performed using a software program (CAST-Grid, Olym-
pus, Denmark) which allowed the application of grid-lines
and points.9 Bone ingrowth, the proportion of woven bone,
grafting material and non-mineralised tissue present in the
gap around the implant were determined on each section.
Bone ingrowth was evaluated by the linear intercept tech-
nique.9 Approximately 250 interceptions on the surface of
each implant were counted and the ingrowth calculated as
bone cover in relation to total surface area and expressed as
Fig. 2
Volume fractions of bone, bone allograft and other tissue were deter-
mined in two zones. Zone 1: 0 mm to 1 mm from implant surface
(implant is black), zone 2: 2 mm to 3 mm from the implanted surface (the











Photomicrographs of a) bone allograft/ProOsteon group without OP-1
device. Bone formation (N) is seen close to the implant. Bone allograft
chips (B) as well as ProOsteon (P) are seen in the gap. b) Bone allograft/
ProOsteon group with OP-1 device. Much woven bone (N) is seen and
ProOsteon is not resorbed. No bone allograft chips can be detected
(undecalcified sections; staining: basic fuchsin and light green; calcified
tissue is green/blue, soft tissue is red, ProOsteon is brown. Magnifica-
tion x 50).
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a percentage. The gap surrounding the implant was divided
into two zones, 0 mm to 1 mm (zone 1), and 2 mm to 3 mm
(zone 2) from the implant surface, with 275 points exam-
ined in each zone at a magnification of 100× (Fig. 1). All
specimens were evaluated blindly.
Reproducibility. The histomorphometric measurements were
performed twice on all sections from the ProOsteon group
and the allograft groups (a total of 12 implants) at an inter-
val of approximately two years by the same person (TBJ).
Reproducibility (intra-observer variation) was calculated as
the coefficient of variation.10
Mechanical testing. Push-out testing was performed using
an Instron universal testing machine (Instron Ltd., High
Wycombe, United Kingdom). Specimens were centralised
over a metal platform with a circular hole supporting the
bone specimen to within 500 µm of the interface.11 The
implant was displaced at a velocity of 5 mm/minute and
load-deformation curves were obtained on an x-y recorder
(PM 8043, Phillips, Eindhoven, The Netherlands). Ultimate
shear strength, apparent stiffness and energy absorption
were estimated from the load-displacement curves, as pre-
viously described.9,11
Statistical analysis. All data are presented as mean values
with standard deviation (SD) in brackets. A two-way analy-
sis of variance was applied and the Student-Newman-Keuls
test was used for all pairwise comparisons between the dif-
ferent groups. The proportions of woven bone, grafting
material and non-mineralised tissue in the gaps were not
compared statistically. A p-value < 0.05 was considered sig-
nificant.
Results
All bacterial cultures from morcellised bone allograft were
sterile. Two dogs were not fully mobile after two weeks and
they were therefore killed before the observation period of
three weeks and excluded from the study. Investigation
showed no sign of infection around the implants.
Histology. Histomorphological findings. Most bone forma-
tion and bone graft resorption was seen at the margins of
the gaps, except in the OP-1-treated specimens, where bone
formation and graft resorption had also occurred close to
the implant surface (Fig. 3). Remnants of the OP-1 collagen
carrier were found in a few gaps. Lacunae due to resorption
of material were recognised on the surface of allograft and
ProOsteon. Non-mineralised tissue was mainly soft and
cell-rich, with no signs of infection.
Histomorphometric findings. Implants not treated with
OP-1 had a mean bone ingrowth of 33% (SD 28), whereas
those with OP-1 had a mean ingrowth of 48% (SD 28).
These differences were not statistically significant (p =
0.50). Where ProOsteon was used alone and when com-
bined with bone allograft there was significantly less new
bone formation in zone 1 than in the other treatment
groups. Only minor differences in bone formation were
seen in zone 2 (Table I). The mean proportion of bone allo-
graft after three weeks in the graft and ProOsteon group
was dramatically reduced, from 9% (SD 1) to 2% (SD 1) in
zone 1 and from 12% (SD 4) to 0% (SD 0) in zone 2 when
OP-1 was added (Table II) but with little difference in the
mean proportion of ProOsteon that could be detected
(Table II).
Mechanical tests. Implants grafted with bone allograft and
ProOsteon with OP-1 had significantly higher energy
absorption than implants grafted with bone allografts and
ProOsteon or ProOsteon alone (Table III). The same ten-
dency was seen in the other mechanical parameters. Analy-
sis of variance found no significant difference for stiffness
among the treatment groups (p = 0.08).
Reproducibility. The coefficient of variation was highest in
the bone allografted group when the proportion of graft
(allograft or ProOsteon) and woven bone was estimated.
Discussion
Aseptic loosening of failed total joint replacements is asso-
ciated with resorption of the surrounding bone. Impaction
of bone allograft has been used to restore the bone bed for
more than a decade, with variable results.2,12 Allograft
bone is associated with the risk of transmitting diseases. By
observing appropriate screening protocols, the risk of viral
transmission is small, with only one reported case of HIV
infection attributed to donated bone allograft.13
The use of bone substitutes as an alternative to bone
graft or as a bone-graft enhancer has previously been stud-
ied clinically and experimentally in vivo by Jensen et al14
and Turner et al,15 and in vitro by Blom et al4 and Verdon-
schot et al.16 Japanese workers have published good clinical
results using HA granules as a substitute to bone graft in
the femur and acetabulum in the revision of failed hip
replacements.3,17 Retrieval studies showed that the major-
ity of the HA granules were incorporated into remodelled
trabeculae at a maximum follow-up of ten years.18 These
promising results are in contrast to the present, and other
experimental studies.14,15 This may be a function of differ-
ence in duration of implantation before analysis was under-
taken, with Oonishi et al18 making observations at up to
ten years and our own being made after only three weeks.
We chose a short observation time for several reasons. The
incorporation of impacted bone allograft is fastest during
the first six months in humans,19 and radiological examin-
ations show little change after two years.20 Furthermore,
the early micromovement of implants is a predictor of early
failure.21 Because bone remodelling in dogs is faster than in
humans, we believe that an observation period of three
weeks is clinically relevant.
In vitro studies have shown excellent stability of femo-
ral stems grafted with a composite of hydroxyapatite and
tricalcium phosphate granules and bone graft.4,16 We
showed that the addition of ProOsteon bone substitute to
bone allograft significantly reduced new bone formation,
but that the addition of OP-1 overcame this problem and
significantly increased bone formation in zone 1 after three
weeks. This suggests that a composite of HA granules and‡
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bone allograft should be modified biologically to reach the
same level of bone incorporation as bone allograft used
alone.
In the present study, the fraction of bone allograft was
much smaller in the OP-1-treated group than in the non-
OP-1-group (Table II), indicating that OP-1 increases not
only bone formation but also resorption of bone allograft.
One major risk of using OP-1 in combination with bone
allograft around weight-bearing implants is uncontrolled
graft resorption.14,22-25 The possible stimulatory effect of
OP-1 on bone resorption is supported clinically by the
experience of Laursen et al,26 who found it to be a primary
event when OP-1 was used to treat unstable thoracolumbar
burst fractures in humans. This might explain early failure
in revision of THR where bone allograft and OP-1 had
been used in combination.27 Adding non-resorbable HA
granules to bone allograft might be a possible way of ensur-
ing the stability of the implant during remodelling of the
bone graft, but our model using a non-weight-bearing
implant does not allow us to make any further comment.
In the present study, we quantified the proportions of
woven newly-formed bone, soft tissue, bone graft and
ProOsteon. We significantly increased implant fixation and
bone formation by adding OP-1 to a composite of bone
allograft and non-resorbable ProOsteon, but none of the
groups was better than bone allograft used on its own.
The authors thank Biomet Inc. for providing the implants, Interpore Inc. for pro-
viding ProOsteon 200 granules, and Stryker Biotech for providing the OP-1.
Table I. Bone ingrowth and proportions of woven formed bone and soft tissue in the gap in percent-
ages (mean (SD))
Woven bone Soft tissue
Bone ingrowth Zone 1 Zone 2 Zone 1 Zone 2
Allograft (n = 6) 32  (28) 27  (6)*,† 34  (4) 51  (8) 44  (7)*,†
ProOsteon (n = 6) 36  (36) 18  (7)‡ 31  (5) 52  (11) 36  (6)
Allograft + ProOsteon (n = 6) 31  (24) 21  (7)‡ 31  (4) 51  (6) 37  (4)
Allograft + ProOsteon + OP-1¶(n = 6) 48  (22) 31  (4) 33  (3) 55  (5) 48  (4)
Statistical analysis applying the Student-Newman-Keuls test
*, p < 0.05 compared with ProOsteon
†, p < 0.05 compared with allograft + ProOsteon
‡, p < 0.05 compared with allograft + ProOsteon + OP-1
¶, OP-1, osteogenic protein 1
Table II. Proportions of grafting materials at three weeks, in percentages (mean (SD)). No statistical compar-
ison was performed




Zone 1 Zone 2 Zone 1 Zone 2 Zone 1 Zone 2 Zone 1 Zone 2
Allograft (n = 6) 22  (5) 23  (6)   -   -   9  (1) 12  (4)   2  (1)   0  (0)
ProOsteon (n = 6)   -   - 31  (10) 33  (4) 19  (3) 20  (3) 14  (13) 20  (3)
*OP-1, osteogenic protein 1








Allograft (n = 6) 299  (287) 2.35  (1.87) 22.5  (23.5)
ProOsteon (n = 6)   79  (115)* 0.72  (0.94)*   5.4  (6.7)
Allograft + ProOsteon (n = 6) 165  (137)* 1.80  (1.49) 15.5  (12.5)
Allograft + ProOsteon + OP-1† (n = 6) 543  (211) 3.66  (1.58) 26.2  (17.9) 
ANOVA‡ p = 0.03 p = 0.04 p = 0.08
*, p < 0.05 compared with allograft + ProOsteon OP-1
†, OP-1, osteogenic protein 1
‡, ANOVA, analysis of variance
Table IV. Coefficient of variation based on double measurements at a two-year interval (percentage)
Woven bone Soft tissue Graft/ProOsteon
Bone 
ingrowth Zone 1 Zone 2 Zone 1 Zone 2 Zone 1 Zone 2
Allograft (n = 6) 6 9 5 3 4 7 12
ProOsteon (n = 6) 9 6 4 2 5 5   6
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dation, Beckett Foundation and the University of Århus supported the study
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